Glaxo places PR business for HIV drugs under review

Share this article:

GlaxoSmithKline has placed the PR business for its HIV medications franchise in review.
The incumbent agency, Chicagobased PCI Public Communications, is not participating in the review.
A GSK spokeswoman declined to comment on the review, citing corporate policy that "any of our agency dealings is confidential."

 

Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.